Auteur/autrice : GRECC

Striking lung cancer response to self-administration of cannabidiol: A case report and literature review, Josep Sulé-Suso et al., 2019

Striking lung cancer response to self-administration of cannabidiol : A case report and literature review Josep Sulé-Suso, Nick A Watson, Daniel G van Pittius, Apurna Jegannathen SAGE Open Medical Case Reports, 2019, 7, 1-4.   Abstract : In spite of new drugs, lung cancer is associated with a very poor prognosis. While targeted therapies are improving outcomes, it is not uncommon for many patients to have only a partial response, and relapse during follow-up. Thus, new drugs or reevaluation of existing therapies used to treat other non-malignant diseases (drug repurposing) are still needed. While this research both in vitro and in vivo is being carried [...]

Lire la suite

Effective connectivity changes in LSD-induced altered states of consciousness in humans, K. Preller et al., 2019

Effective connectivity changes in LSD-induced altered states of consciousness in humans Katrin H. Preller, Adeel Razib, Peter Zeidman, Philipp Stämpflif, Karl J. Friston, and Franz X. Vollenweider Proceedings of the National Academy of Sciences ,· January 2019 DOI: 10.1073/pnas.1815129116 Abstract : Psychedelics exert unique effects on human consciousness. The thalamic filter model suggests that core effects of psychedelics may result from gating deficits, based on a disintegration of information processing within cortico–striato–thalamo-cortical (CSTC) feedback loops. To test this hypothesis, we characterized changes in directed (effective) connectivity between selected CTSC regions after acute administration of lysergic acid diethylamide (LSD), and after pretreatment with Ketanserin (a selective serotonin [...]

Lire la suite

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population, P.S. Hendricks et al., 2015

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population Peter S Hendricks, Christopher B Thorne, C Brendan Clark, David W Coombs, and Matthew W Johnson Journal of Psychopharmacology · January 2015 DOI: 10.1177/0269881114565653 ·   Abstract : Mental health problems are endemic across the globe, and suicide, a strong corollary of poor mental health, is a leading cause of death. Classic psychedelic use may occasion lasting improvements in mental health, but the effects of classic psychedelic use on suicidality are unknown. We evaluated the relationships of classic psychedelic use with psychological distress and suicidality among over 190,000 USA [...]

Lire la suite

Reducing the risks of drug use: The case for set and setting, P. Dalgarno, D. Shewan, 2005

Reducing the risks of drug use: The case for set and setting PHIL DALGARNO & DAVID SHEWAN Addiction Research and Theory,  2005, 13, 3, 259–265   Abstract : The central proposition of this article is that if people are thoughtful, well-prepared and aware of the means and best environments for using a particular drug, then the risks associated with the use of a particular drug – any drug – can be minimal. The types of drugs discussed in this context focus on those assumed to be the most ‘addictive’ – heroin and cocaine – to those less well-known but potentially more hazardous to use without [...]

Lire la suite

Ceremonial ‘Plant Medicine’ use and its relationship to recreational drug use : an exploratory study, C. Dorsen et al., 2018

Ceremonial ‘Plant Medicine’ use and its relationship to recreational drug use : an exploratory study Caroline Dorsen, Joseph Palamar and Michele G. Shedlin Addiction Research & Theory, 2018 https://doi.org/10.1080/16066359.2018.1455187   ABSTRACT Background : The ceremonial use of psychoactive/hallucinogenic plant based drugs, such as ayahuasca, psilocybin and others, is a growing trend in the United States (US) and globally. To date, there has been little research documenting how many people are using psychoactive substances in this context, who the users are, what benefits/risks exist in the use of these drugs and the relationship between ceremonial drug use and recreational drug use. In this paper we describe a [...]

Lire la suite

The Dualistic Model of Passion Applied to Recreational Marijuana Consumption, Alan K. Davis, 2017

Model of Passion Applied to Recreational Marijuana Consumption Alan K Davis, Addiction Research & Theory, 2017, 25, 3,  188-194 Published online 2016 Dec 5. doi: 10.1080/16066359.2016.1242722   Abstract : This study was designed to evaluate the application of the dualistic model of passion (Vallerand, 2015; Vallerand et al., 2003) to recreational marijuana consumption. Using a web-based recruitment and data collection procedure, an online sample of 524 frequent marijuana consumers were administered a modified version of the Passion Scale (Marijuana-Harmonious and Obsessive Passion Scale; M-HOPS) and other questionnaires. Results from a canonical correlation analysis indicated that obsessive passion scores were significantly positively associated with past 30-day consumption, [...]

Lire la suite

American Story ! De la prohibition des opiacés (1914) à la crise des opioïdes (1995-2018), Dr Bertrand Lebeau, 2018

American Story ! De la prohibition des opiacés (1914) à la crise des opioïdes (1995-2018) Dr Bertrand Lebeau Leibovici, CSAPA Valjean, Montfermeil (93), 2018.   Du Harrison Act (1914) aux années 30 La grande vague de prohibition née dans les années 1880 dans le monde occidental aboutit aux premières conférences internationales (Shanghaï, 1909, et La Haye, 1912). Dans le même temps, les premières législations nationales apparaissent aux Etats-Unis (1914), en France (1916), en Grande-Bretagne (1920). Précédant de 5 ans la « loi sèche » (Volstead Act) de 1919 qui prohibera l’alcool durant 15 ans, le Harisson Act vise à interdire la production, l’importation et la [...]

Lire la suite

The Anti-Inflammatory Properties of Terpenoids from Cannabis, Ruth Gallily et al., 2018

The Anti-Inflammatory Properties of Terpenoids from Cannabis Ruth Gallily, Zhannah Yekhtin, and Lumı´r Ondrˇej Hanusˇ Cannabis and Cannabinoid Research, 3, 1, 2018, 282-290. Doi : 10.1089/can.2018.0014   Abstract : Introduction : Cannabinoids are well known to have anti-inflammatory effects in mammalians; however, the Cannabis plant also contains other compounds such as terpenoids, whose biological effects have not yet been characterized. The aim of this study was to compare the anti-inflammatory properties of terpenoids with those of cannabidiol (CBD). Materials and Methods : Essential oils prepared from three monoecious nonpsychoactive chemotypes of Cannabis were analyzed for their terpenoid content and subsequently studied pharmacologically for their anti-inflammatory properties in [...]

Lire la suite

How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review, Eva Hoch et al., 2019

How effective and safe is medical cannabis as a treatment of mental disorders ? A systematic review Eva Hoch,· Dominik Niemann, · Rupert von Keller, · Miriam Schneider, · Chris M. Friemel, · Ulrich W. Preuss ,·Alkomiet Hasan, · Oliver Pogarell European Archives of Psychiatry and Clinical Neuroscience, 2019 Doi.org/10.1007/s00406-019-00984-4   Abstract : We conducted a review of systematic reviews (SRs) and randomized-controlled trials (RCTs) to analyze efficacy and safety of cannabis-based medication in patients with mental disorders. Five data bases were systematically searched (2006—August 2018); 4 SRs (of 11 RCTs) and 14 RCTs (1629 participants) were included. Diagnoses were: dementia, cannabis and opioid dependence, psychoses/schizophrenia, general [...]

Lire la suite

Le Parlement Européen favorable au développement du Cannabis thérapeutique, 13 février 2019

Take medical use of cannabis seriously, say MEPs   Press Releases , Plenary session , ENVI  13-02-2019 - 17:46   http://www.europarl.europa.eu/news/en/press-room/20190207IPR25221/take-medical-use-of-cannabis-seriously-say-meps The EU should stimulate innovation in medical cannabis  Effective cannabis-based medicines should be covered by health insurance schemes  Authorities should distinguish clearly between medical and other uses  www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//TEXT+TA+20190213+TOC+DOC+XML+V0//EN&language=EN MEPs propose ways to address research gaps on medical cannabis and call on member states to seize the potential of cannabis-based medicines. In a resolution adopted on Wednesday, MEPs call on the Commission and national authorities to draw a clear distinction between medical cannabis and other uses of cannabis. The resolution urges the Commission and member [...]

Lire la suite